Biodesy, Inc. Enters into Research Collaboration with Amgen

Biodesy, Inc. announced today that it has entered into a research collaboration agreement with Amgen Inc. (Thousand Oaks, Calif.) to support Amgen’s neuroscience drug discovery programs. Biodesy will apply its proprietary technology to screen and characterize novel chemical matter against a clinically relevant target, based on direct, real-time measurements of the structural changes induced by associated molecular interactions. Under the terms of the agreement, Biodesy is eligible to receive compensation for assay development and for screening Amgen’s fragment library.

Biodesy Inc. Completes $15.0 Million Series A Financing and Appoints Greg Yap as Chief Executive Officer

Biodesy, Inc., a privately held developer of novel systems to analyze real-time protein function for research and clinical applications, announced today that it has closed a $15.0 million Series A venture financing round from 5AM Ventures, Pfizer Venture Investments and Roche Venture Fund. In addition, Greg Yap has been named Chief Executive Officer and a Director.


Webinar: Measure Protein Conformational Change in Real Time

December 03, 2015

Biodesy would like to invite you to attend a live educational webinar about the Biodesy Delta technology. This live webinar will take place on December 3, 2015 at 10:00 AM PST and will feature Joshua Salafsky, Ph.D., Biodesy’s founder and Chief Scientific Officer.

To RSVP for this informational session, please use the link below:

The webinar will last less than 30 minutes, including a live Q&A.

SLAS 2016

January 23 - 27, 2016 San Diego, CA, USA

Visit Biodesy at booth #1549 at the SLAS Expo!